• Explore /
  • Poster
  • / Indirect treatment comparison of the efficacy of olaparib 300 mg tablets BID and cabazitaxel 25 mg/m<sup>2</sup> every 3 weeks plus daily prednisolone and granulocyte colony-stimulating factor in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Indirect treatment comparison of the efficacy of olaparib 300 mg tablets BID and cabazitaxel 25 mg/m2 every 3 weeks plus daily prednisolone and granulocyte colony-stimulating factor in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Abstract Video & Slides Poster

Authors

null

Tim Reason

Estima Scientific, London, United Kingdom

Tim Reason , Charles McCrea , Robert Hettle , Sameer Ghate , Christian Heinrich Poehlein , David Olmos

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

NCT02987543

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 5051)

DOI

10.1200/JCO.2021.39.15_suppl.5051

Abstract #

5051

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Johann S. De Bono

First Author: Elena Castro

First Author: Neal D. Shore

First Author: Alexandra Sokolova